My main research interest is studying risk factors for cardiovascular and kidney disease. I am particularly interested in factors mediating the excess risk of cardiovascular disease among patients with various stages of kidney disease, from pre-clinical to end-stage as well as improving estimates of kidney disease prevalence and consequences. I have enjoyed looking at genetic and biologic risk factors as well as innovative epidemiologic methods and statistical analysis in the conduct of this research. The ultimate objective of this research is to decrease the enormous burden of cardiovascular and kidney disease through developing the scientific basis for behavioral and pharmacologic interventions. More recently I developed an interest in the vascular basis of dementia, co-leading a team in the design of the ARIC Neurocognitive Study. In addition, methodologic tools and pathophysiologic insights are sought which would have broader applications.

Program leadership at Hopkins: * Director, Cardiovascular Epidemiology Training Program (T32HL07024) and area of concentration.

* Director, George W. Comstock Center for Public Health Research and Prevention (GWCC). GWCC includes 2 units with 26 staff members. The Health Monitoring Unit (HMU) on Pennsylvania Avenue includes the CLUE studies and leads training and public health activities. The Surveillance & Disease Prevention Unit (S&DP) on the square in Hagerstown, Maryland, houses the ARIC study (includes county-wide heart disease surveillance), CHS, GEM and SHHS.

My research projects include leadership roles in:

* Atherosclerosis Risk in Communities Study - A prospective study of 15,792 individuals recruited in 1986-1988 and followed to 2012 for cardiovascular disease and a wide range of other conditions. The study also includes community surveillance for heart disease incidence trends in four communities. This NHLBI funded multi-center contract provides the basis for a wide range of ancillary studies which results in a total productivity averaging more than 50 publications annually. We hope to have a 25-year follow-up examination in 2011-2013.

* Kidney Disease Collaborative Studies - Co-chairing the National Kidney Foundation guidelines on the definition and classification of kidney disease lead to an ongoing line of research. The (CKD-EPI) collaboration involves pooling individual level data to improve estimating equations for kidney function based on serum creatinine and novel markers. The 2009 CKD-EPI Creatinine Equation may replace the MDRD Study equation as the most widely used equation to estimate GFR. Additional studies focus on discovery and validation of novel markers for CKD staging and progression. We are currently helping to lead a collaborative effort to pool data from the leading cohorts on CKD prognosis to assist in refining the definition and staging of CKD.

* NHANES Kidney Disease Studies - Ongoing efforts to provide the most valid estimates of kidney disease prevalence in the U.S. as well as examine concurrent complications and consequences. Our grants measured and made available to the scientific community data on serum cystatin C and other novel measures of kidney function using stored specimen.

* CHOICE study - A prospective study of dialsis patients patients which includes a large specimen bank.

National committees: My role as vice-chair of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) workgroup for the Clinical Practice Guideline “Chronic Kidney Disease: Evaluation, Classification and Stratification” has lead to ongoing involvement in the international effort to address the public health burden of chronic kidney disease. This has included contributing to Kidney Disease Improving Global Outcomes(KDIGO) initiative planning controversies meetings in 2004 and 2009 and in 2007 attending NIH and CDC working groups.

Epidemiology, Cardiovascular Epidemiology, Kidney Disease, Genetic Epidemiology, Research Methods, Heart, Kidney

2005 American Epidemiological Society (AES) membership 2003 Inaugural Fellow American Heart Association Council on the Kidney in Cardiovascular Disease 1998,2001 Advising, Mentoring & Teaching Recognition Award, JHU-SHPH 1999 Fellow, American Heart Association Council on Epidemiology and Prevention

* Click for list of all Coresh J citations in PubMed [218 entries on 10/22/2009]

* 2009 publication highlights

Levey AS, Stevens LA, Schmid CH, Yaping (Lucy) Zhang L, Castro A*, MPH2, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). Development of a New Equation to Estimate Glomerular Filtration Rate and Comparsion to the Modification of Diet in Renal Disease Study Equation. Ann Int Med. 2009; 604-612.

Genome-wide association papers:

Senior author on: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 41, 407-414 (2009).

In 2008 Co-senior author on Gout GWAS: Lancet. Oct 2008. DOI:10.1016/S0140-6736(08)61343-4

Middle author on GWAS publications on: Stroke - N Engl J Med. 2009; 360:1718. Blood pressure - Nat Genet. 2009 May 10. ECG QT interval Nat Genet. 2009 Apr; 41(4):388-9 In 2008: Height,

For genetic admixture collaborations see Wen-Hong (Linda) Kao's faculty web page.

Cognitive function: Alonso A, Mosley T, Gottesman R, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalization associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009 Aug 19.

Basic science collaborations: Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10338-42. Epub 2009 Jun 8.

* Frequently cited (see www.scopus.com):

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47.

Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, for Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Expressing the MDRD study equation for estimating GFR with standardized serum creatinine values. Clin Chem. 2007; 53(4):766-72.

National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39:(2)S1-S266, 2002. (Workgroup Vice-Chair: J Coresh)

Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1)1-12.

Myers G, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clinical Chemistry 2006: 52(1):5-18.

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145:247-54.

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100.

Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic Kidney Disease Awareness, Prevalence, and Trends among U.S. Adults, 1999 to 2000. J Am Soc Nephrol. 2005;16(1):180-8.

Manjunath G, Tighiouart H, Ibrahim I, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41(1):47-55.

Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63(3):1121-1129.

Coresh J, Astor B, McQuillan G, Kusek J, Green T, Van Lente F, Levey AS. Calibration and Random Variation of the Serum Creatinine Assay As Critical Elements of Using Equations to Estimate Glomerular Filtration Rate. Am J Kid Dis 2002; 39(5):920-929.

Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, and Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101 (19):2239-2246

Levey A, Hogg R, Balk E, Lau J, Eknoyan G, Steffes M, Levin A, Coresh J. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. Ann Intern Med 2003;139(2):137-147.

Sarnak MJ, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Levey AS. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 2003; 108(17):2154-69. Also published in Hypertention 2003; 42(5)1050-1065.

Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz G, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; l 11(6): 1416-21.

* Other favorites:

Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS; Family Investigation of Nephropathy and Diabetes Research Group. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008 Oct;40(10):1185-92.

Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291(4):451-9.

Astor B, Arnett DK, Brown A, Coresh J. Association of Kidney Function and Hemoglobin with Left Ventricular Morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2004; 43(5)845-846.

Haroun MK, Jaar BG, Hoffman S, Comstock GW, Klag MJ, Coresh J. Risk Factors for Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington County, Maryland. J Am Soc Nephrol. 2003; 14(11):2934-2941.

Kao WHL, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL. Pro12Ala of the peroxisome proliferators-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52(6):1568-1572.

Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J. Interleukin-6 haplotypes, inflammation, and risk of cardiovascular disease in a multi ethnic dialysis cohort. J Am Soc Nephrol. 2006; 17(3):863-70.

Hsu CC, Bray MS, Kao WHL, Pankow JS, Boerwinkle E, Coresh J. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol. 2006; 17(2):504-12.

Hallan SI, Coresh J, Astor BC, Åsberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J. International comparison of the relationship of chronic kidney disease prevalence and end-stage renal disease risk. J Am Soc Nephrol. 2006; 17(8):2275-84.

Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996; 143(10):1059-68.

Selvin E, Coresh J, Brancati F. The burden and treatment of diabetes in elderly persons in the U.S. Diabetes Care. 2006; 29: 2415-2419.

Shoham DA, Vupputuri S, Diez Roux AV, Kaufman JS, Coresh J, Kshirsagar AV, Zeng D, Heiss G. Kidney disease in life course socioeconomic context: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2006 (in press)

Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS. Apolipoprotein E and Progression of Chronic Kidney Disease. JAMA. 2005; 293(23):2892-9.

Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR. Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease. Ann Intern Med. 2005; 143(3):174-83.

Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol. 2003; 14(6):1568-1577.

Muntner P, Coresh J, Klag MJ, Whelton PK, Perneger TV. Exposure to radiologic contrast media and an increased risk of treated end-stage renal disease. Am J Med Sci 2003; 326(6):353-9.

Pastor-Barriuso R, Gullar E, Coresh J. Transition models for change-point estimation in logistic regression. Stat Med 2003; 22(7):1141-1162.

Eustace JA, Coresh J, Kutchey C, Te PL, Gimenez LF, Scheel PJ, Walser M. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kid Int 2000; 57:2527-38.

Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kid Int 2000;58:293-301.